Study of Irinotecan Liposome Injection in Patients With Advanced Biliary Tract Cancer

NCT05009953 · clinicaltrials.gov ↗

PHASE2

Phase

TERMINATED

Status

17

Enrollment

INDUSTRY

Sponsor class

Stopped Internal strategy change. Not related to safety concerns.

Conditions

Advanced Biliary Tract Cancer
Intrahepatic Cholangiocarcinoma
Extrahepatic Cholangiocarcinoma
Gallbladder Carcinoma

Interventions

DRUG: Irinotecan Liposome Injection
DRUG: SG001
DRUG: Fluorouracil
DRUG: Leucovorin

Sponsor

CSPC Ouyi Pharmaceutical Co., Ltd.